“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

04 June 2019
Pharma

Visiongain has published a new pharma report Global Antifungal Drugs Market Forecast 2019-2029: Azoles, Echinocandins, Polyenes, Allylamines, Voriconazole, Posaconazole, Clotrimazole, Isavuconazole, Fluconazole, Caspofungin, Micagunfin, Amphotericin, Lamisil, Dermatophytosis, Aspergillosis, Candidiasis.

The global antifungal drugs market is estimated to have reached $14bn in 2018 and is expected to grow at a CAGR of 3.8% during the forecast period. In 2018, the global antifungal drugs market was dominated by Azoles.

This report profiled the selected companies: Abbott Laboratories, Bayer AG, Enzon Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Kramer Laboratories, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Sanofi S.A. and others.

The lead analyst commented that "Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

The antifungal drugs market is mainly driven by the incidence and prevalence rate of antifungal infections. Moreover, cost-effective products, growing population of immunocompromised individuals and minimal side-effects are other factors that will drive market growth. However, antifungal drugs market has some restraints such as the presence of alternative therapies."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever